Advanced Non-Small Cell Lung Cancer (NSCLC) treatment strategies are experiencing unprecedented innovation through the development of bispecific antibody therapeutics. These sophisticated molecular constructs represent the next generation of precision oncology, offering dual-targeting capabilities that traditional single-agent therapies cannot match. As researchers continue to advance...